Bax and Bcl-2 are a pair of important genes that control programmed cell death, or apoptosis, with Bax being the apoptosis promoter and Bcl-2 the apoptosis protector. Although the detailed mechanism is unknown, the protein products of these two genes form protein dimers with each other and the relative ratio of the two proteins is believed to be a determinant of the balance between life and death. In our preliminary study, we found that K562 erythroleukemia cells have an extremely low level of endogenous Bcl-2 expression and a fairly high level of endogenous Bax expression. We constructed Bax and Bcl-2 expression vectors and transfected them into K562 cells. We found that transfection of Bax vector increased the expression of Bax protein; a shortened form of Bax also appeared. Cell death analysis using the Annexin V assay showed that the Bax vector caused signi®cantly more apoptotic cells that the Bcl-2 or pCI-neo vector did. After selection with G418, Bax, Bcl-2 and pCI-neo stably transfected cells were established. These three cell lines were examined for their response to the chemotherapeutic agents ara-C, doxorubicin, etoposide and SN-38. Bax-K562 cells showed signi®cantly higher fractions of apoptotic cells than pCI-neo-K562 cells when treated with ara-C, doxorubicin or SN-38. No sensitization eect was seen when etoposide was used. In contrast, Bcl-2-K562 cells had fewer apoptotic cells than pCI-neo-K562 cells after treatment with all these agents. Therefore, Bax may sensitize K562 cells to apoptosis induced by a wide range of, but not all, chemotherapeutic agents.
Introduction
The ecacy of chemotherapeutic agents depends on their eectiveness in inducing apoptosis of tumor cells. Dierent tumor cells respond to dierent chemotherapeutic agents in dierent ways. Understanding the mechanisms that underlie these dierent responses will aid in the design of speci®c therapy regimens. Studies of the last 10 years have identi®ed the Bcl-2 family as a key regulator of cell death (Yang and Korsmeyer, 1996) . The Bcl-2 family includes a series of homologous genes, such as Bax, Bcl-2, Bcl-X L , Bad and others. The members of the Bcl-2 family have yin-yang roles in apoptosis regulation. These is strong evidence that Bcl-2 represses apoptosis induced by radiation (Strasser et al., 1994) , various chemotherapeutic agents (Ibrado et al., 1996; Zhang et al., 1996; Yin and Schimke, 1996) , cytokine depletion (Oltvai et al., 1993) and other cytotoxic conditions. It has been shown that Bax homodimerizes with itself and that a Bax/Bax dimer accelerates programmed cell death under some conditions, such as during interleukin-3 (IL-3) depletion (Oltvai et al., 1993) . Recently, using a reverse tetracycline-inducible system, it was shown that Bax expression induced apoptosis in Jurkat cells (Xian et al., 1996) . Members with opposite functions regulate each other by forming complexes with a new function. Therefore, the ratio of the levels of Bax and Bcl-2 is more important than the steady-state level of each individual protein in the cells. However, the exact roles played by the Bax protein are rather dicult to de®ne, perhaps because Bax also forms complexes with other cellular proteins and because dierent cells may tolerate dierent steady-state levels of Bax protein. Along this line, it has been shown that Bax protein is expressed in many normal tissues (Krajewski et al., 1994) and that Bax-transfected stable cell lines can be established (Oltvai et al., 1993) . Therefore, it is important to know whether Bax can induce apoptosis in cell lines that already express high levels of endogenous Bax.
Bax may also aect the response of cancer cells to chemotherapeutic agents and the clinical prognosis of cancer patients. Reduced expression of Bax was found to be associated with poor response rates to combination chemotherapy and shorter survival in women who had metastatic breast cancer (Krajewski et al., 1995) . Overexpression of Bax sensitized human breast cancer cells to radiation-induced (Sakakura et al., 1996) and epirubicin-induced (Wagener et al., 1996) apoptosis. Another study showed that Bax enhanced apoptosis in ovarian cancer cell lines, which were transfected with Bax gene expression vector, after treatment with paclitaxel, vincristine, or doxorubicin (Strobel et al., 1996) .
In this study, we investigated the role of Bax and Bcl-2 in the response of K562 erythroleukemia cells to cell death induced by a series of chemotherapeutic agents. The results suggest that Bax can selectively sensitize K562 cells to cell death induced by some chemotherapeutic agents. Bcl-2 protects these cells from apoptosis induced by all the agents used.
Results

Bax and Bcl-2 protein expression in transfected K562 cells
In a Western blotting survey of expression levels of Bax and Bcl-2 proteins in a series of leukemia cell lines, we found that Bcl-2 protein expression was very low in erythroleukemia K562 cells. In contrast, Bax protein was expressed at a high level (Figure 1 ). This expression pattern is rather intriguing to us because K562 cells are relatively resistant to apoptosis, which is not consistent with the cells' low levels of apoptosis-inhibiting Bcl-2 and high levels of apoptosis-facilitating Bax. In view of the ®ndings that Bax and Bak (another Bcl-2 analogue) can inhibit apoptosis under dierent conditions and in dierent cell lines (Reed, 1997) , there is a possibility that in K562 Bax may have an apoptosis-inhibitory function. However, this expression pattern does not necessarily argue against the traditional roles of Bax and Bcl-2 in K562 cells: many other factors may determine the threshold steady-state levels that would aect apoptotic response. For example, K562 cells are p53-null and express the bcr-abl oncogene, which was shown to inhibit apoptosis (Zhang et al., 1994; McGahon et al., 1994) . To demonstrate the roles of Bax and Bcl-2 in the apoptosis response of K562 cells, we decide to use a gene transfer technique to modulate the expression of Bax and Bcl-2 and analyse for cell death in the presence and absence of additional death stimuli. Bax and Bcl-2 cDNAs were cloned into the expression vector pCI-neo, and Bax, Bcl-2 and pCI-neo control expression vectors were then transfected into K562 cells by electroporation. The cells killed by electroporation were removed by Ficoll separation 4 h after electroporation. Under our electroporation condition, 40 ± 50% of cells are routinely transfected. Two days after electroporation, Bax and Bcl-2 proteins were analysed by Western blotting. In Bax-transfected K562 cells, the original form of Bax, which we named Bax(L), increased, and a smaller form of Bax, which we named Bax(S), appeared. The appearance of Bax(S) is very interesting because our previous studies showed that this form of Bax was associated with apoptosis in three leukemia cell lines (Kobayashi et al., submitted) . Bcl-2 protein expression was very low in K562 cells but was clearly detected in Bcl-2-transfected cells (Figure 1 ).
Bax modestly induced apoptosis in K562 cells
The Bax-, Bcl-2-, and pCI-neo-transfected cells were analysed for apoptosis. The Annexin V assay was used because of its simplicity and sensitivity in detecting early stage apoptosis (Koopman et al., 1994; Martin et al., 1995; Boersma et al., 1996; van Engeland et al., 1996) . In this assay, annexin V-FITC binds to phosphatidylserine, which during apoptosis is externalized to the outer cell membrane and is recognizable on the cell membrane of only apoptotic cells. The results showed that electroporation itself caused background levels of apoptotic cells and that pCI-neo vector and Bcl-2 vector transfection resulted in only slightly higher levels of apoptotic cells, probably because of the toxic eect of DNA on the cells. In contrast, Bax-transfected cells had twice as many apoptotic cells as cells transfected by Bcl-2 vector or pCI-neo control vector (Figure 2 ). The dierences in the numbers of apoptotic cells were statistically signi®cant. Therefore, elevated Bax expression can induce increased apoptosis in K562 Bax sensitizes K562 cells to apoptosis induced by a series of chemotherapeutic agents
Consistent with Bax being a weak cell death promoter for K562 cells, Bax stably transfected cells were established after G418 selection. Western blotting showed that the Bax(S) was retained in the stable cell line. Bcl-2-and pCI-neo-transfected cells were also established. These cells allowed us to examine whether Bax can sensitize K562 cells to chemotherapeutic agent-induced apoptosis. The Bax-, Bcl-2-and pCIneo-transfected K562 cells were treated with 2 mM ara-C, 0.4 mg/ml doxorubicin, 20 mg/ml etoposide or 2 mM SN-38 (topoisomerase type I inhibitor) continuously for 3 days. On each day of experiment, cells were taken from the culture and analysed for apoptosis by Annexin V assay. The results in Figure 3 show that Bax-transfected cells were more sensitive to ara-C-, doxorubicin-, and SN-38-induced cell death than were pCI-neo-transfected cells. However, Bax-transfected cells were not more sensitized to etoposide. Bcl-2 overexpression repressed apoptosis in all treatments used here compared with pCI-neo control vectortransfected K562 cells. Bcl-2-K562 cells also had a lower percentage of spontaneously apoptotic cells compared with Bax-K562 and pCI-neo-K562 cells. We should point out that the cells we used in these experiments were not individual clones but total populations obtained after G418 selection. Therefore, the results re¯ect a true population-average phenomenon. The results were also highly reproducible, and except in one instance, dierences in the levels of apoptosis were statistically signi®cant.
Discussion
Since the Bcl-2 family was discovered, identi®cation of its many members has snowballed. These members interact with each other and regulate the important cellular process of apoptosis involved in tissue development, homeostasis and tumor cell response to chemotherapy and radiotherapy (Yang and Korsmeyer, 1996) . In this study, we investigated the roles of Bax and Bcl-2 in an erythroleukemia cell line, K562, which is p53-null. We were interested in this cell line because K562 cells have very low levels of endogenous Bcl-2 and abundant expression of endogenous Bax protein, despite the cells' noted resistance to many chemotherapeutic agents and radiation (McGahon et al., 1994; Kobayashi et al., 1995) . Although the lack of p53 and presence of bcr ± abl may contribute to the highly resistant nature of K562 cells, it is also possible that Figure 3 Bax sensitizes K562 cells to apoptosis induced by ara-C, doxorubicin and SN-38, but not by etoposide. After electroporation with Bax, Bcl-2 or pCI-neo vectors, K562 cells were continuously cultured for more than 4 weeks in the presence of G418 to establish stable cell lines, K562-Bax, K562-Bcl-2 and K562-pCI-neo. These three cell lines were cultured in the presence of chemotherapeutic agents ara-C, doxorubicin, SN-38 or etoposide. At dierent treatment time, cells were taken and analysed for apoptosis by Annexin V assays. Results from three independent experiments were shown Bax and Bcl-2 play nontraditional roles in apoptosis regulation in these cells. Reports showed that Bcl-2 indeed can promote apoptosis in some cases and that the apoptosis facilitator Bak can inhibit apoptosis in certain situations (Reed, 1997) . Apoptosis is accompanied by a loss of membrane phospholipid integrity, resulting in the externalization of phosphatidylserine to the cell surface. The¯uorochrome conjugated protein Annexin V binds to phosphatidylserine on the cell surface, this binding can be detected by¯ow cytometry, which renders this assay a sensitive method to analyse apoptosis (Koopman et al., 1994; Martin et al., 1995; Boersma et al., 1996; van Engeland et al., 1996) . Therefore, the Annexin V assay was the method of choice in the present study. Our analysis using a gene transfer system demonstrated that Bax overexpression can modestly induce apoptosis of K562 cells and can sensitize K562 cells to cell death induced by some chemotherapeutic agents. In a study using a reverse tetracycline system, it was recently demonstrated that Bax expression alone, without additional death stimulus, can induce apoptosis in Jurkat cells (Xian et al., 1996) . Parental Jurkat cells express a very low level of endogenous Bax protein. The K562 cells we used in this study express high levels of endogenous Bax protein; nevertheless, further Bax overexpression induced apoptosis. It thus appears that only when Bax is expressed over a threshold can apoptosis be induced, and that threshold seems to dier from cell line to cell line.
It was recently reported that Bax overexpression sensitized human ovarian tumor cells to paclitaxel, vincristine and doxorubicin, but not to carboplatin, etoposide and hydroxyurea (Strobel et al., 1996) . In the present study, we used ara-C, doxorubicin, etoposide and SN-38. We also found that Bax overexpression failed to sensitize K562 cells to etoposide-induced apoptosis. These ®ndings suggest that the sensitization eect of Bax is not universal but selective. One intriguing aspect is that this selectivity is not necessarily dependent on the chemotherapeutic agent used. For example, two studies reported that Bax does sensitize cells to etoposide-induced apoptosis. Bax antagonized Bcl-X L during etoposide-and cisplatininduced cell death in the murine IL-3-dependent cell line FL5.12 (Simonian et al., 1996a) , and Bax de®ciency promoted resistance in doxorubicin-, etoposide-and cisplatin-induced apoptosis in mouse embryonic ®broblasts derived from p53 and bax knockout mice (McCurrach et al., 1997) . However, in those reports, murine cell lines were used. It remains unclear whether Bax overexpression has dierent eects of the etoposide-induced apoptosis of human and murine cells.
In our experiment, Bax overexpression did not sensitize K562 cells to etoposide. However, Bcl-2 overexpression protected K562 cells from etoposideinduced apoptosis. This result provides an argument that Bax does not counteract every aspect of Bcl-2-regulated apoptosis and that Bax and Bcl-2 have independent mechanisms regulating apoptosis. It is also conceivable that other apoptosis-promoting members of the Bcl-2 family may counteract Bcl-2 in the regulation of etoposide-induced apoptosis. By the same token, protein dimerization among Bcl-2 family members is not the only mechanism through which apoptosis regulation occurs. It has been reported that Bax antagonizes Bcl-X L during drug-induced cell death, independent of its heterodimerization with Bcl-X L (Simonian et al., 1996a) . A recent report showed that Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death (Simonian et al., 1996b) . Further study into the regulation of apoptosis induced by dierent chemotherapeutic agents may help dissect the molecular pathways through which members of the Bcl-2 family communicate to coordinate the cell death process.
Materials and methods
Cell culture K562 erythroleukemia cell line was obtained from the American Type Culture Collection (Rockville, MD). K562 cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum in a 378C incubator containing 5% CO 2 .
DNA transfection
Bax and Bcl-2 expression vectors were prepared by inserting Bax or Bcl-2 cDNA into the EcoRI cloning site of the pCI-neo vector (Promega). Electroporation was used to transfect expression plasmids into K562 cells, under the conditions described previously (Zhang et al., 1994) . Four hours after electroporation, cells killed by electroporation were removed by Ficoll. For stable transfection, cells were selected in medium containing 0.8 mg/ml G418 (Life Technologies Inc.) for 4 weeks.
Treatment of stable cell lines with chemotherapeutic agents
Stable cell lines of K562 cells transfected with Bax, Bcl-2 or pCI-neo vector were treated by continuous exposure to 0.4 mg/ml doxorubicin (Ben Venue Laboratories, Inc., Bedford, OH), 2 mM cytosine b-D-arabinofuranoside (ara-C) (Sigma Chemical Co., St. Louis, MO), 20 mg/ml etoposide (Bristol-Myers Squibb Co., Princeton, NJ) or 2 mM SN-38 (active agent of CPT-11, a topoisomerase type I inhibitor) (Yakurt Inc., Tokyo, Japan).
Western blotting
Total cellular protein was extracted and analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS ± PAGE) as described previously (Zhang et al., 1994) . After being transferred to an Immobilon membrane (Millipore, Bedford, MA), the proteins were incubated overnight with antibodies against Bcl-2 (Dako Co.), Bax (Krajewski et al., 1994) , p53 (Ab-6) (Oncogene Science), and actin (Ab-1) (Oncogene Science). The levels of protein were analysed using the enhanced chemiluminescence system (Amersham Corp.) according to the manufacturer's instructions..
Apoptosis analysed by Annexin V assay
Cell suspensions at a concentration of 4610 6 were stained with Annexin V-FITC conjugate (Nexins Research, The Netherlands) in calcium-containing binding buer at a dilution of 1:100. After 10 min of incubation on ice, data were acquired on a FACScan¯ow cytometer (Becton Dickinson, Santa Cruz, CA) at 488 nm laser excitation and emission acquired at FL1. Data was analysed using the Lysis II Software (Becton Dickinson).
Statistical analysis
P-values were determined by Student's t test.
